These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 26643931)

  • 1. Safety and tolerability of a cell culture derived trivalent subunit inactivated influenza vaccine administered to healthy children and adolescents: A Phase III, randomized, multicenter, observer-blind study.
    Nolan T; Chotpitayasunondh T; Capeding MR; Carson S; Senders SD; Jaehnig P; de Rooij R; Chandra R
    Vaccine; 2016 Jan; 34(2):230-236. PubMed ID: 26643931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
    Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the immunogenicity and safety of 3 inactivated hepatitis A vaccines in Korean children aged 12 to 18 months: An open-label, randomized, prospective, multicenter study.
    Hong SS; Choi UY; Ma SH; Lee SY; Han SB; Kim KH; Kang JH; Kim JH
    Medicine (Baltimore); 2019 Feb; 98(6):e14364. PubMed ID: 30732169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of two doses of an inactivated hepatitis a vaccine given 6 months apart in healthy toddlers, children, and adolescents aged 12 months to 15 years in China: a phase IV study.
    Shi N; Rasuli A; Thollot Y
    Hum Vaccin Immunother; 2019; 15(3):748-754. PubMed ID: 30403910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging to detect local tissue reactions after vaccination in sheep in vivo.
    Bernau M; Kremer-Rücker PV; Kreuzer LS; Schwanitz S; Cussler K; Hoffmann A; Scholz AM
    Vet Rec Open; 2017; 4(1):e000200. PubMed ID: 29018531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study.
    Turner PJ; Southern J; Andrews NJ; Miller E; Erlewyn-Lajeunesse M;
    BMJ; 2015 Dec; 351():h6291. PubMed ID: 26645895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza Vaccine Effectiveness and Uptake in Children at Risk of Severe Disease.
    Blyth CC; Jacoby P; Effler PV; Kelly H; Smith DW; Borland ML; Willis GA; Levy A; Keil AD; Richmond PC;
    Pediatr Infect Dis J; 2016 Mar; 35(3):309-15. PubMed ID: 26646548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Rudenko L; Isakova-Sivak I; Naykhin A; Kiseleva I; Stukova M; Erofeeva M; Korenkov D; Matyushenko V; Sparrow E; Kieny MP
    Lancet Infect Dis; 2016 Mar; 16(3):303-10. PubMed ID: 26673391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9).
    Sobhanie M; Matsuoka Y; Jegaskanda S; Fitzgerald T; Mallory R; Chen Z; Luke C; Treanor J; Subbarao K
    J Infect Dis; 2016 Mar; 213(6):922-9. PubMed ID: 26655841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ineffectiveness of the 2014-2015 H3N2 influenza vaccine.
    Mandelboim M; Glatman-Freedman A; Drori Y; Sherbany H; Pando R; Sefty H; Zadka H; Shohat T; Keller N; Mendelson E
    Oncotarget; 2016 Jan; 7(2):1185-92. PubMed ID: 26716420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior infection with influenza virus but not vaccination leaves a long-term immunological imprint that intensifies the protective efficacy of antigenically drifted vaccine strains.
    Kim JH; Liepkalns J; Reber AJ; Lu X; Music N; Jacob J; Sambhara S
    Vaccine; 2016 Jan; 34(4):495-502. PubMed ID: 26706277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in U.S. hospitalizations and inpatient deaths from pneumonia and influenza, 1996-2011.
    Chang DH; Bednarczyk RA; Becker ER; Hockenberry JM; Weiss PS; Orenstein WA; Omer SB
    Vaccine; 2016 Jan; 34(4):486-494. PubMed ID: 26706275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza vaccine effectiveness for hospital and community patients using control groups with and without non-influenza respiratory viruses detected, Auckland, New Zealand 2014.
    Pierse N; Kelly H; Thompson MG; Bissielo A; Radke S; Huang QS; Baker MG; Turner N;
    Vaccine; 2016 Jan; 34(4):503-509. PubMed ID: 26685091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013: The Importance of Two Priming Doses.
    Thompson MG; Clippard J; Petrie JG; Jackson ML; McLean HQ; Gaglani M; Reis EC; Flannery B; Monto AS; Jackson L; Belongia EA; Murthy K; Zimmerman RK; Thaker S; Fry AM
    Pediatr Infect Dis J; 2016 Mar; 35(3):299-308. PubMed ID: 26658375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertussis specific cell-mediated immune responses ten years after acellular pertussis booster vaccination in young adults.
    Gröndahl-Yli-Hannuksela K; Kauko L; Van Der Meeren O; Mertsola J; He Q
    Vaccine; 2016 Jan; 34(3):341-9. PubMed ID: 26643932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review.
    Bansal A; Trieu MC; Mohn KGI; Cox RJ
    Front Immunol; 2021; 12():744774. PubMed ID: 34691051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2021-2022.
    Can Commun Dis Rep; 2021 Sep; 47(9):372-380. PubMed ID: 34650334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summary of the NACI Supplemental Statement on Mammalian Cell Culture-Based Influenza Vaccines.
    Sinilaite A; Gemmill I; Harrison R
    Can Commun Dis Rep; 2020 Oct; 46(10):324-332. PubMed ID: 33316000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax
    Lamb YN
    Drugs; 2019 Aug; 79(12):1337-1348. PubMed ID: 31372959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.